AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Smoking is one of the main risk factors for non-small cell lung cancer (NSCLC). Other factors include exposure to radon or asbestos and a family history of lung cancer. You can take steps to ...

Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ...

A genetic mutation in the lungs can cause non-small cell lung cancer (NSCLC). Different mutations can affect your treatment decisions and outcomes. Genetic testing after a diagnosis of NSCLC is ...

A new deep learning model predicts which NSCLC patients will respond to immunotherapy, outperforming some traditional ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...